Loading...
XNASTGTX
Market cap4.48bUSD
Jan 08, Last price  
28.77USD
1D
2.75%
1Q
31.79%
Jan 2017
518.71%
Name

TG Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:TGTX chart
P/E
353.42
P/S
19.17
EPS
0.08
Div Yield, %
0.00%
Shrs. gr., 5y
14.50%
Rev. gr., 5y
333.86%
Revenues
234m
+8,290.02%
0000000019,048152,381152,381152,381152,381152,381152,000152,000152,0006,689,0002,785,000233,662,000
Net income
13m
P
-5,896,031-19,140,997-9,695,123-12,032,252-4,268,858-2,793,285623,645-853,074-18,072,719-20,478,210-55,781,277-62,948,646-78,252,894-118,476,012-173,482,000-179,347,000-285,878,000-355,552,000-203,831,00012,672,000
CFO
-31m
L-82.17%
-5,690,445-6,244,942-7,750,738-10,229,711-4,444,009-1,049,799-1,970,113-86,577-5,187,964-10,824,231-35,059,919-44,690,272-61,591,330-93,763,562-128,925,000-132,806,000-214,507,000-295,634,000-176,170,000-31,413,000
Earnings
Feb 26, 2025

Profile

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
URL
https://www.tgtherapeutics.com/
IPO date
Dec 14, 1995
Employees
244
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
233,662
8,290.02%
2,785
-58.36%
Cost of revenue
213,452
259,670
Unusual Expense (Income)
NOPBT
20,210
(256,885)
NOPBT Margin
8.65%
Operating Taxes
390
5,496
Tax Rate
1.93%
NOPAT
19,820
(262,381)
Net income
12,672
-106.22%
(203,831)
-42.67%
Dividends
Dividend yield
Proceeds from repurchase of equity
46,296
584
BB yield
-1.83%
-0.04%
Debt
Debt current
2,892
1,581
Long-term debt
120,026
93,404
Deferred revenue
6,016
305
Other long-term liabilities
71,440
Net debt
(94,590)
(91,501)
Cash flow
Cash from operating activities
(31,413)
(176,170)
CAPEX
(14)
Cash from investing activities
(50,651)
(20,013)
Cash from financing activities
72,705
(391)
FCF
(27,110)
(262,135)
Balance
Cash
217,508
174,082
Long term investments
12,404
Excess cash
205,825
186,347
Stockholders' equity
(1,514,210)
(1,526,887)
Invested Capital
1,792,969
154,659
ROIC
2.04%
ROCE
7.25%
EV
Common stock shares outstanding
148,508
135,411
Price
17.08
44.38%
11.83
-37.74%
Market cap
2,536,525
58.34%
1,601,915
-36.24%
EV
2,441,935
1,510,414
EBITDA
20,633
(256,370)
EV/EBITDA
118.35
Interest
12,615
10,191
Interest/NOPBT
62.42%